Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huh?? Who is Sheikh? Another conspiracy by the failed 13Ders?
It's funny how those who squandered their money on IncellDx while predicting it would be acquired by CYDY after the failed hostile takeover by the 13Dumpster gang. Still laughing...
This has nothing to do with my post. ???
I did and there's nothing in there to show he sold most of his shares.
What proof do you have of that?? LMAO
Please reread my post. I did NOT say it's not required. I said it's ALREADY BEEN PAID. Good grief!
There is NO REASON for Amarex to extend the deadline because it's ALREADY BEEN PAID. Good grief!!!
Amarex is NOT getting the $6.5m. It was a BOND that was posted by CYDY!
We closed up almost 10%. LMAO
What does ANY of this have to do with your claim they haven't paid Samsung or the bond because there was no PR?? LAUGHING!!!!!!!!
And what evidence do you have that Samsung is suing?? LAUGHING!!!
VERY likely given companies don't issue PRs when they pay their bills. LMFAO
How's India working out with who?? Yeah, that's really high on their priority list! LMAO
How do you know they haven't already paid the bond?? And the bond is hardly on their radar given the potential deals they may be working on for NASH and mTNBC, not to mention the ongoing covid trials in Brazil. Monday night might be it?? LMFAO
I looked at the profile and there's really nothing there. I suspect they just put Allen Allen in that slot for now because they can't remove the position.
What "terrible" articles were published by Sheikh and how were they "terrible" for CytoDyn? LMAO
"Terrible" is when a failed 13D promoter foolishly puts all of their money into promoting IncellDX in the empty hope that it would be acquired by CytoDyn. And now they can't get their money out of it, so they continue to bash CytoDyn. Now THAT's "terrible". Those failed 13Ders never learn.
Promoters?? Yeah, NP was paying promoters instead of the bills. LMAO
NP is still living rent-free in the heads of the failed 13D promoters. Nothing to pay there.
Sure, they're all working for free now. Good catch! And they're now hiring more people who will work for free. LMAO
Easy answer. Call them.
It was never on the table. Just a BS talking point for shorts.
BTW, haven't seen any 8ks lately for fund raising. The shorts will spin that by saying nobody's buying which is laughable. Even the Paulson reps have been told to keep quiet and cannot discuss any offerings or current events at this time. Anyone who can't see there's a deal on the table isn't looking.
WRONG! Paulson doesn't lend them money. Paulson is paid with a share of the revenue that comes from selling their shares. Laughing...
One week prior to the Vyera announcement that started the share price increase by 900% within the next few weeks. LMAO!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152644074
There is a cult that hates him and they spread lies to destroy him. So those lies must be exposed constantly. It's a never ending thing. He lives in their head rent-free and no doubt laughing.
WRONG!
From Jake2212 on another board:
My take on Amarex stipulation re bond. The joint stipulation extends the bond posting date to Feb 4, with an option to further extend it to Feb 14, and also dismisses NSF without prejudice. Several board members have already posted their assessments re the meaning and/or consequences of the stip, and I agree with most of what I have read. For instance, dismissing NSF is inconsequential. This lawsuit is about compelling the transfer of clinical trial data and an accounting of Amarex's billed services. If the accounting generates a tort claim, NSF will be an additional defendant and it will be facing potential joint liability if it either assumed Amarex's liabilities at acquisition or it controlled Amarex's working relationship with CYDY.
However, what I find most interesting about the stip is why CYDY sought a 20 (and potentially 30) day delay on posting the $6.5M bond (which also delays by the same number of days the data transfer and the accounting). CYDY will have to either buy the bond or post the cash. Either way, shares will presumably have to be sold by management at a discount to the current sp. Why then does management expect the sp to increase significantly in less than 20 days?
(By the way, I find it hard to believe that the sudden CC cancellation was driven by the looming joint stipulation. The Amarex lawsuit was not even referenced in the original PR announcing the CC and it would have been easy to have deflected any shareholder question involving it.) So what would likely move the sp significantly within 14 to 20, or perhaps 25 days? Well, great results on Nash 700 mg and/or confirmation that most of the cancer patients are still alive (with resubmittal of BTD request) would definitely help the sp short term, but how much and for how long would be hard to say
I can only envision 2 things that would move the sp by dollars, instead of dimes: a Nash partnership deal or a credible BO proposal. Of these 2, the former obviously seems a far more likely possibility than the latter.
But just to take all of this unsupported speculation on my part to its outer limits, allow me to reference Weasel's post from yesterday in which he opined that the most likely eventual BO suitor for CYDY would be Samsung. I agree with his analysis. As he stated: Samsung's parent holding company announced last summer that it would make several billion dollars available to underwrite Samsung's entry into the US Pharma market; and Samsung has previously demonstrated great confidence in Leronlimab as a potential platform drug by carving out precious manufacturing capacity for poor little CYDY. Add to this, that Samsung has no shareholders to complain (or revolt) about a 2 digit billion dollar offer to buy a struggling OTC biopharma and LL would not cannibalize Samsung's existing drugs because it has none. Finally, if Samsung truly believes in the efficacy of LL in anything close to the way ohm does and has any intention to acquire CYDY, now would be the time make its move -- before CYDY enters into a Nash partnership that would create an unwelcome loose end.
To be abundantly clear: I have no inside info; I have had no communications of any kind with CYDY management/staff; and all of the above is sheer conjecture on my part. It's very hard to solve a puzzle when you don't have most of the pieces, but it's something to do on a long weekend before the NFL playoff games start. Have a great weekend.
I see we're up to $.74 in Europe on large volume this morning. May be another interesting day if the rally continues.
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
CytoDyn previously hit a primary endpoint in a pivotal Phase 3 HIV trial with some HTE patients; over 20 patients remain in an extension arm study for up to 4 years
CytoDyn will include some findings from this study in its BLA submission for HIV approval
VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that a research paper entitled “Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects” has been accepted, peer reviewed and is available as a journal pre-proof on ScienceDirect. ScienceDirect provides access to a large bibliographic database of scientific and medical publications of the Dutch publisher Elsevier. This article is available for purchase from Elsevier through a link on CytoDyn’s website:
LERONLIMAB (PRO 140) ACTIVITY AGAINST 4-CLASS DRUG RESISTANT HIV-1 FROM HEAVILY TREATMENT EXPERIENCED SUBJECTS - ScienceDirect
This project was a collaborative effort among scientists and researchers from:
University of Milan, Milan, Italy
University of Siena, Siena, Italy
University of Rome Tor Vergata, Rome, Italy
San Raffaele Vita-Salute University, Milan, Italy
Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy
Azienda Ospedaliera San Paolo, Milan, Italy
University of Perugia, Perugia, Italy; 8 Santa Maria Annunziata Hospital, Florence, Italy; 9 University of Brescia, Brescia, Italy.
The study was conducted as an in-vitro study of 25 HIV-1-infected patients harboring a documented 4-class drug-resistance nucleoside reverse transcriptase inhibitors (“NRTIs”), non-nucleoside reverse transcriptase inhibitors (“NNRTIs”), protease inhibitors (“PIs”), and integrase strand transfer inhibitors (“INSTIs”) enrolled in the Italian PRESTIGIO Registry.
Significant findings from the study and observations from the authors include:
Leronlimab maintained full activity in the presence of extensive resistance to the four main antiviral classes.
Leronlimab IC50 did not appear significantly altered by previous or current exposure to maraviroc.
In vitro, leronlimab and maraviroc have been reported to have synergistic activity, further corroborating the different mechanism of the two drugs despite the same CCR5 target.
In vitro susceptibility to leronlimab is not affected by extensive drug resistance and exposure to maraviroc.
Leronlimab may have some advantages over maraviroc as a clinically valuable CCR5 antagonist, including lower toxicity, less drug-drug interaction issue and less frequent dosing.
Leronlimab can play a key role in subjects with very limited therapeutic options and CCR5-tropic virus.
“We would like to thank our Italian colleagues for understanding the importance of leronlimab in the treatment of HIV. This is further proof that leronlimab can benefit CCR5 tropic HIV patients, including those patients with multidrug resistance. HIV patients deserve the opportunity for multiple, effective treatment options,” said CytoDyn’s Chief Medical Officer, Scott A. Kelly M.D.
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “I would like to thank Dr. Stefano Rusconi, who had reached out to us to do this study. We are grateful to him and his colleagues for producing what we believe to be further evidence that leronlimab can play a vital role in the treatment of HIV. We believe leronlimab has many advantages, including protecting healthy cells from viral entry, prevention of HIV transmission, convenience, lower toxicity, and the ability to treat patients across the full spectrum of disease from treatment-naive to 4-class resistant HIV. Many HIV patients could also be in danger of developing NASH and, with our recent 350 mg open label NASH trial having achieved its primary (PDFF) and secondary (cT1) endpoints, we believe that all HIV patients may benefit from a CCR5 product as part of their medication. We also believe leronlimab’s potential role in cancer treatment could help HIV patients with a long history of HIV (especially heavily treatment experienced HIV), which increases their risk of developing cancer.”
ANYONE who wants the truth about Tony C's PROSTAGENE/Pestell debacle can read Tony C's PR bragging about it. LOL
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167424959
It's funny how some try to pin Tony C's ProstaGene/Pestell fiasco on NP when all they have to do is a simple Google search:
CytoDyn Completes Acquisition of ProstaGene and Names Dr. Richard G. Pestell to Board of Directors
“Richard is a driving force in CCR5 antagonist research and we gain significant expertise and intellectual property with this acquisition that advances the development of PRO 140 as a novel cancer metastasis therapeutic,” said Anthony D. Caracciolo, CytoDyn’s Chairman. “We are privileged to have Richard join CytoDyn to expand our executive and scientific team, and we enthusiastically welcome him as the newest member of our board of directors.”
Under the terms of the definitive agreement, CytoDyn acquired substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell. The aggregate transaction consideration consisted of 27,000,000 shares of CytoDyn common stock. One-fifth of the stock consideration is being held back for distribution over an 18-month escrow period, to the extent not needed to satisfy indemnity claims. Approximately one-half of the stock consideration otherwise distributable to Dr. Pestell (approximately 8.3 million shares) is restricted and subject to vesting and forfeiture upon certain events over a three-year period. The total transaction value, based on the $0.5696 closing share price for CytoDyn common stock on November 15, 2018, was approximately $15.4 million.
https://www.cytodyn.com/newsroom/press-releases/detail/299/cytodyn-completes-acquisition-of-prostagene-and-names-dr
PROSTAGENE DEBACLE ON CARACCIOLO’S WATCH
The ProstaGene acquisition was essentially about a prostate cancer diagnostic. The concept of the acquisition was masterminded by Executive Anthony Caracciolo who at the time was CytoDyn’s Executive Chairman of the Board when the deal was initially announced in July 2018. Nader Pourhassan was the CEO, but at the time had no decision-making power with respect to the acquisition. Many investors may not realize, but the executive chairman is higher in rank than CEO and Caracciolo stepped into that role in January 2017. Many thought that his Gilead resume would be instrumental in inking a deal. On closing of the acquisition in November 2018 Dr. Pestell was not only welcomed as the newest board member, but was also the company’s Interim Chief Medical Officer. This was all Caracciolo’s doing until a more balanced board led by Dr. Scott Kelly came to fruition in January 2019 . The fact is Caracciolo didn’t resign until January 10, 2019 when David Welch joined the board. So issues that predate January 10, 2019 are on Caracciolo’s watch, not Pourhassan’s.
An interesting anecdote is that Caracciolo also presided over the failed receptor occupancy test done by IncellDX.
Fortunately, CYDY has many catalysts that will make this nothing less than a great buying opportunity. It could have been worse like HGEN that's down from $30 to $3 and has no future. For CYDY, this is just a short-term drop. Can't wait to see the Topline Report for NASH!
They CANNOT discuss the 700mg results until the topline report has been released! LMFAO
So you're suggesting they release the science BEFORE they complete the topline report??? LMAO
Wrong! They're not going to discuss the results until the topline report has been released. LOL
They're still working on the 700mg topline report. Why would there be any mention of the results when they're still compiling them???
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
Primary endpoint (PDFF) was achieved in both Intention to Treat and Per Protocol Populations
VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The trial was conducted in two parts. Part 1 compared a 700 mg weekly dose and placebo in a double-blind randomized manner and Part 2 evaluated a 350 mg weekly dose as an open label study compared to the same placebo blinded arm. Results of the topline report will be announced when available.
The primary endpoint, PDFF (proton density fat fraction), is an MRI-derived biomarker for fatty deposition, while the secondary endpoint, cT1, is an iron-corrected T1 mapping representative of liver inflammation and fibrosis. These two values are used to evaluate the risk of NASH. CytoDyn’s Phase 2 clinical trial compared the changes from baselines in these endpoints. The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant. Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1. There were no significant differences in treatment emergent adverse events between leronlimab and placebo groups.
Christopher P. Recknor, M.D., CytoDyn’s Senior Executive Vice President of Clinical Operations, stated, “We thank our sites, vendors and staff who helped make this trial possible. We are in the process of analyzing biomarker data including CCR5 haplotype information to better understand responder rates and mechanism of action. Given 5% of the world population is estimated to have NASH with 20% progressing to cirrhosis, this signal gives hope for a therapeutic intervention for this disease.”
Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “We wish to thank our entire NASH team led by Dr. Recknor, who has done a phenomenal job conducting this study. We are very excited about these results and the potential for helping the millions of individuals effected by NASH across the world. The main focus after seeking approval in the U.S. will be the UK, Canada, Brazil, and the Philippines. Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique drug with tremendous opportunities.”
Again?? For who - 13D, IncellDX and Amarex? LMFAO
CytoDyn and NP won every judicial decision and lawsuit last year! Let's hope for a repeat in 2022!
Nah...Tony C. is stuck on the ProstaGene bus because nobody has or will forget how he squandered 27m shares on a failed company, but there are some who wish it would quietly go away. LMAO
Can you tell me what value the shareholders got for that boondoggle? Just one - anything?
PROSTAGENE DEBACLE ON CARACCIOLO’S WATCH
The ProstaGene acquisition was essentially about a prostate cancer diagnostic. The concept of the acquisition was masterminded by Executive Anthony Caracciolo who at the time was CytoDyn’s Executive Chairman of the Board when the deal was initially announced in July 2018. Nader Pourhassan was the CEO, but at the time had no decision-making power with respect to the acquisition. Many investors may not realize, but the executive chairman is higher in rank than CEO and Caracciolo stepped into that role in January 2017. Many thought that his Gilead resume would be instrumental in inking a deal. On closing of the acquisition in November 2018 Dr. Pestell was not only welcomed as the newest board member, but was also the company’s Interim Chief Medical Officer. This was all Caracciolo’s doing until a more balanced board led by Dr. Scott Kelly came to fruition in January 2019 . The fact is Caracciolo didn’t resign until January 10, 2019 when David Welch joined the board. So issues that predate January 10, 2019 are on Caracciolo’s watch, not Pourhassan’s.
An interesting anecdote is that Caracciolo also presided over the failed receptor occupancy test done by IncellDX.
You mean like the failed COB Tony C. who squandered millions purchasing the failed company, ProstaGene? Yes, he was COB for seven years and accomplished absolutely nothing!
Nader's ProstaGene debacle?? LMAO
Where do you see Nader's name mentioned in this PR?
CytoDyn Completes Acquisition of ProstaGene and Names Dr. Richard G. Pestell to Board of Directors
“Richard is a driving force in CCR5 antagonist research and we gain significant expertise and intellectual property with this acquisition that advances the development of PRO 140 as a novel cancer metastasis therapeutic,” said Anthony D. Caracciolo, CytoDyn’s Chairman. “We are privileged to have Richard join CytoDyn to expand our executive and scientific team, and we enthusiastically welcome him as the newest member of our board of directors.”
Under the terms of the definitive agreement, CytoDyn acquired substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell. The aggregate transaction consideration consisted of 27,000,000 shares of CytoDyn common stock. One-fifth of the stock consideration is being held back for distribution over an 18-month escrow period, to the extent not needed to satisfy indemnity claims. Approximately one-half of the stock consideration otherwise distributable to Dr. Pestell (approximately 8.3 million shares) is restricted and subject to vesting and forfeiture upon certain events over a three-year period. The total transaction value, based on the $0.5696 closing share price for CytoDyn common stock on November 15, 2018, was approximately $15.4 million.
https://www.cytodyn.com/newsroom/press-releases/detail/299/cytodyn-completes-acquisition-of-prostagene-and-names-dr